

Mechanism of Squalene Cyclization: The Chiral Origin of the C-22 Hydrogen Atoms of Fusidic Acid

By E. CASPI* and R. C. EBERSOLE

(The Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545)

and W. O. GODTFREDSSEN and S. VANGEDAL

(Leo Pharmaceutical Products, Ballerup, Denmark)

Summary The C-2 protons of mevalonic acid are incorporated with retention of configuration into C-22 of fusidic acid; this finding excludes the intermediacy of products with a $\Delta^{20(22)}$ double bond in the formation of a $\Delta^{17(20)}$ double bond in fusidic acid.

THE difficulty^{1,2} of rationalizing the collapse of cation (1)³ to protosterol antibiotics like fusidic acid (2a) and others⁴ all having the *Z* geometry at $\Delta^{17(20)}$ has been pointed out. Stabilization of (1) through direct elimination of the 17 β -proton (route 'a') would lead according to Cornforth's hypothesis^{3b} to the wrong geometry about the 17(20) double bond.^{1,2} Additionally in such a process the cyclase system of *F. coccineum* would be expected to obviate the backbone rearrangement³ through a kinetically controlled stabilization of (1) (route 'a'). In contrast during the enzymatic transformation of (1) into lanosterol, it has been suggested that the cyclase system exerts only a marginal influence.⁵

The interpretational difficulty could be alleviated were the formation of (2a) to proceed through a $\Delta^{20(22)}$ intermediate (3a) (1; route 'b') as noted by Corey *et al.*⁶ for the analogue (3b). Enzymatic isomerization of (3a) could afford (2a) (origin of C-22 hydrogens not assigned). Rotation around C-17(20) of (3a) would permit positioning of the side chain and the 17-hydrogen suitable for the formation of a $\Delta^{17(20)}$ double bond in (2a).


The presence of a $\Delta^{20(22)}$ intermediate was supported by an observation that incubation^{1,7} of (3*RS*;2*S*)-[2-¹⁴C,2-³H]-mevalonic acid (MVA) (³H:¹⁴C ratio 5.26:1 atomic ratio 1:1) with *F. coccineum* gave *S*-fusidic acid (2a) with a ³H:¹⁴C ratio of 4.65:1, corresponding to the incorporation of 5.3 atoms of tritium and 6 atoms of ¹⁴C. In the case of *R*-fusidic acid (2a) biosynthesized from (3*RS*,2*R*)-[2-¹⁴C,2-³H]-MVA (³H:¹⁴C ratio 5.15:1) the ³H:¹⁴C ratio of 5.04:1 corresponded to an atomic ratio of 6:6. The results with (2*S*)-[2-¹⁴C,2-³H]-MVA could be interpreted as arising from the

TABLE



Experiment with:		I; (2 <i>R</i>)-[2- ³ H,2- ¹⁴ C]MVA ³ H: ¹⁴ C ratio			II; (2 <i>S</i>)-[2- ³ H,2- ¹⁴ C]MVA ³ H: ¹⁴ C ratio			
No.	Product	Derivative counted	¹⁴ C-Spec. act. ^a	Isotopic	Atomic	¹⁴ C-Spec. act. ^a	Isotopic	Atomic
1.	Mevalonic acid	<i>N</i> -Diphenylmethylamide	8.79	5.15	1.02:1	4.75	5.26	1.13:1
2.	Methyl fusidate	(2 <i>b</i>)	86.7	5.04	6.00:6	82.4	4.65	6.00:6
3.	Methyl dihydrofusidate ..	(2 <i>c</i>)	85.6	5.05	6.00:6	82.5	4.62	5.96:6
4.	6-Methylheptane-1,2-diol ..	(4 <i>b</i>)	30.2	4.92	1.95:2	29.0	4.58	1.97:2
5.	5-Methylhexan-1-al	(4 <i>d</i>)	30.4	5.04	2.00:2	29.0	4.66	2.00:2
6.	4-Methylpentan-1-ol	(5 <i>c</i>)	2.7	5.02	1.99:2	4.0	4.60	1.98:2
7.	4-Methylpentan-1-al	(6 <i>b</i>)	1.5	3.02	1.20:2	4.9	4.54	1.95:2
8.	Methyl 4-methylpentanoate ..	(6 <i>d</i>)	—	—	—	—	2.38	1.02:2

^a D.p.m. per mmol × 10⁴; entries 1, 6 and 7 were counted at higher dilutions.

loss of a 22-*pro-S* hydrogen *via* pathway [*b'* shown in (1)] in the biosynthesis of (2*a*). The specimens of *R* and *S*-fusidic acid were thus degraded as shown in the Scheme and the chirality and ³H content at C-22 determined.



oxidation of the alcohol (5*b*) to aldehyde (6*a*) proceeded without loss of tritium. Hence if (5*b*) had a tritium atom at C-1 the alcohol must have the 1*S* configuration. Consequently the diene^{1,12} (7) (from *S*-fusidic acid) was oxidized¹³ to (6*c*) which was purified as the methyl ester (6*d*) by g.l.c. The ³H:¹⁴C ratio of (6*d*) indicates that of the two ³H atoms present in (5*b*) only one was retained. Therefore



SCHEME

a; i H₂; ⁹ ii CH₂N₂. b; i O₃; ii LiAlH₄. c; H₅IO₃. d; i CF₃-COOH; ^{10b} ii LiAlH₄; iii prep. g.l.c. e; NAD⁺-Yeast alcohol dehydrogenase (YADH). f; i LiCl-HCO-NMe₂; ¹² ii CH₂N₂. g; i RuO₄; ¹³ ii CH₂N₂; iii prep. g.l.c.

The products† obtained from *R*-fusidic (Table; Experiment I; entries 2—6) exhibited ³H:¹⁴C ratios which corresponded to the predicted^{1,8} atomic ratios. One atom of tritium‡ was lost on the NAD⁺-YADH oxidation of (5*b*) to (6*a*) (Experiment I; entries 6, 7), thus establishing the 1*R* configuration of the alcohol.¹¹

The products from the *S*-fusidic acid had constant ³H:¹⁴C ratios (Experiment II; entries 2—7). Clearly NAD⁺-YADH

† All the compounds were homogenous by g.l.c. or t.l.c. Derivatives were identified by n.m.r., mass, and i.r. spectroscopy, *etc.*, and by comparison with authentic samples.

‡ The removal of only 0.8 atom of tritium may have been caused by partial air oxidation of the alcohol (see ref. 11).

one atom of tritium must be present at C-1 of (5*b*) and (6*a*). It follows that a tritium atom originating from (2*S*)-[2-¹⁴C,-2-³H]-MVA is present at the 22-*pro-S* position of the derived *S*-fusidic acid.

The results demonstrate that the C-2 protons of MVA are incorporated into C-22 of fusidic acid with retention of their stereochemical integrity. The intermediacy of a Δ²⁰⁽²²⁾

precursor is thus excluded. Because the C-13 hydrogen of fusidic acid is derived from the 4-*pro R* proton of MVA,¹ Δ^{12} or $\Delta^{13(17)}$ intermediates also cannot be involved in the biosynthesis. Hence it seems that the stabilization of (1) in the formation of (2a) cannot be rationalized solely on an organic chemical basis⁵ without some enzyme participation.¹

This work was supported by Grants from the National Institutes of Health. The authors thank Dr. L. J. Mulheirn for preliminary experiments.

(Received, 7th August 1972; Com. 1382.)

- ¹ L. J. Mulheirn and E. Caspi, *J. Biol. Chem.*, 1971, **246**, 2494; E. Caspi and L. J. Mulheirn, *J. Amer. Chem. Soc.*, 1970, **92**, 404.
² L. J. Mulheirn and P. J. Ramm, *Chem. Soc. Rev.*, 1972, **1**, 259.
³ (a) A. Eschenmoser, L. Ruzicka, O. Jeger, and D. Arigoni, *Helv. Chim. Acta*, 1955, **38**, 1890; (b) J. W. Cornforth, *Angew. Chem. Internat. Edn.* 1968, **7**, 903.
⁴ (a) T. G. Halsall, E. R. H. Jones, G. Lowe, and C. E. Newall, *Chem. Comm.*, 1966, 685; P. Oxley, *ibid.*, p. 729; (b) S. Okuda, S. Iwasaki, M. I. Sair, Y. Machida, A. Inoue, K. Tsuda, and Y. Nakayama, *Tetrahedron Letters*, 1967, 2295; W. von Daehne, H. Lorch, and W. O. Godtfredsen, *ibid.*, 1968, 4843.
⁵ E. E. van Tamelen and J. H. Freed, *J. Amer. Chem. Soc.*, 1970, **92**, 7206; E. E. van Tamelen, R. P. Hanzlik, R. B. Clayton, and A. L. Burlingame, *ibid.*, p. 2137.
⁶ E. J. Corey, P. R. O. de Montellano, and H. Yamamoto, *J. Amer. Chem. Soc.*, 1968, **90**, 6255; E. J. Corey, K. Lin, and H. Yamamoto, *ibid.*, 1969, **91**, 2132.
⁷ W. O. Godtfredsen, W. von Daehne, S. Vangedal, A. Marquet, D. Arigoni, and A. Melera, *Tetrahedron*, 1965, **21**, 3505.
⁸ G. Popjak and J. W. Cornforth, *Biochem. J.*, 1966, **101**, 553.
⁹ W. O. Godtfredsen and S. Vangedal, *Tetrahedron*, 1962, **18**, 1029.
¹⁰ (a) J. B. Greig, K. R. Varma, and E. Caspi, *J. Amer. Chem. Soc.*, 1971, **93**, 760; (b) M. F. Hawthorne, W. D. Emmons, and K. S. McCallum, *ibid.*, 1958, **80**, 6393.
¹¹ J. B. Greig, K. R. Varma, and E. Caspi, *J. Amer. Chem. Soc.*, 1971, **93**, 760; E. Caspi, K. R. Varma, and J. B. Greig, *Chem. Comm.*, 1969, 45; K. R. Varma and E. Caspi, *J. Org. Chem.*, 1969, **34**, 2489.
¹² W. O. Godtfredsen, W. von Daehne, and S. Vangedal, *Chem. Comm.*, 1966, 638.
¹³ D. M. Piatak, H. B. Bhat, and E. Caspi, *J. Org. Chem.*, 1969, **34**, 112; D. M. Piatak, G. Herbst, J. Wicha, and E. Caspi, *ibid.*, p. 116.